JP2019522681A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019522681A5 JP2019522681A5 JP2019519615A JP2019519615A JP2019522681A5 JP 2019522681 A5 JP2019522681 A5 JP 2019522681A5 JP 2019519615 A JP2019519615 A JP 2019519615A JP 2019519615 A JP2019519615 A JP 2019519615A JP 2019522681 A5 JP2019522681 A5 JP 2019522681A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- salt
- substituted
- hydrate
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 66
- 201000011510 cancer Diseases 0.000 claims 52
- 150000001875 compounds Chemical class 0.000 claims 39
- 206010006187 Breast cancer Diseases 0.000 claims 36
- 208000026310 Breast neoplasm Diseases 0.000 claims 36
- 150000003839 salts Chemical class 0.000 claims 31
- 239000012453 solvate Substances 0.000 claims 25
- 239000000825 pharmaceutical preparation Substances 0.000 claims 24
- 102000015694 estrogen receptors Human genes 0.000 claims 16
- 108010038795 estrogen receptors Proteins 0.000 claims 16
- 102000003998 progesterone receptors Human genes 0.000 claims 14
- 108090000468 progesterone receptors Proteins 0.000 claims 14
- 238000010276 construction Methods 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 10
- 206010046766 uterine cancer Diseases 0.000 claims 10
- 208000032383 Soft tissue cancer Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 6
- 206010033128 Ovarian cancer Diseases 0.000 claims 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims 6
- 208000029742 colonic neoplasm Diseases 0.000 claims 6
- 201000005787 hematologic cancer Diseases 0.000 claims 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 6
- 201000005202 lung cancer Diseases 0.000 claims 6
- 208000020816 lung neoplasm Diseases 0.000 claims 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 6
- 201000001441 melanoma Diseases 0.000 claims 6
- 201000002528 pancreatic cancer Diseases 0.000 claims 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 6
- 201000000849 skin cancer Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 208000009956 adenocarcinoma Diseases 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 201000007455 central nervous system cancer Diseases 0.000 claims 4
- 208000030381 cutaneous melanoma Diseases 0.000 claims 4
- 230000006801 homologous recombination Effects 0.000 claims 4
- 238000002744 homologous recombination Methods 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 210000001428 peripheral nervous system Anatomy 0.000 claims 4
- 229940127557 pharmaceutical product Drugs 0.000 claims 4
- 201000008261 skin carcinoma Diseases 0.000 claims 4
- 101001113440 Homo sapiens Poly [ADP-ribose] polymerase 2 Proteins 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 claims 3
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims 3
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 claims 3
- 102000004243 Tubulin Human genes 0.000 claims 3
- 108090000704 Tubulin Proteins 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010007282 Carcinoid tumour pulmonary Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 2
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 2
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 2
- 201000004458 Myoma Diseases 0.000 claims 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000010505 Nose Neoplasms Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims 2
- 206010034299 Penile cancer Diseases 0.000 claims 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 201000011165 anus cancer Diseases 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 210000000941 bile Anatomy 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 201000002797 childhood leukemia Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 230000008472 epithelial growth Effects 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 208000024519 eye neoplasm Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 210000004392 genitalia Anatomy 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 201000006866 hypopharynx cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 208000026807 lung carcinoid tumor Diseases 0.000 claims 2
- 201000000564 macroglobulinemia Diseases 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- -1 methylazetidinyl Chemical group 0.000 claims 2
- 208000037830 nasal cancer Diseases 0.000 claims 2
- 201000006958 oropharynx cancer Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 208000010916 pituitary tumor Diseases 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 230000001172 regenerating effect Effects 0.000 claims 2
- 208000037968 sinus cancer Diseases 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 210000000115 thoracic cavity Anatomy 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- 208000037965 uterine sarcoma Diseases 0.000 claims 2
- 206010046885 vaginal cancer Diseases 0.000 claims 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021192564A JP2022037004A (ja) | 2016-06-24 | 2021-11-26 | 癌の治療に有用なｐａｒｐ１、ｐａｒｐ２、および／またはチューブリンの阻害剤としてのフタラジン誘導体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662354449P | 2016-06-24 | 2016-06-24 | |
| US62/354,449 | 2016-06-24 | ||
| US201662426095P | 2016-11-23 | 2016-11-23 | |
| US62/426,095 | 2016-11-23 | ||
| PCT/US2017/039119 WO2017223516A1 (en) | 2016-06-24 | 2017-06-23 | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021192564A Division JP2022037004A (ja) | 2016-06-24 | 2021-11-26 | 癌の治療に有用なｐａｒｐ１、ｐａｒｐ２、および／またはチューブリンの阻害剤としてのフタラジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019522681A JP2019522681A (ja) | 2019-08-15 |
| JP2019522681A5 true JP2019522681A5 (enExample) | 2021-05-20 |
| JP7033588B2 JP7033588B2 (ja) | 2022-03-10 |
Family
ID=59297390
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019519615A Active JP7033588B2 (ja) | 2016-06-24 | 2017-06-23 | 癌の治療に有用なｐａｒｐ１、ｐａｒｐ２、および／またはチューブリンの阻害剤としてのフタラジン誘導体 |
| JP2021192564A Pending JP2022037004A (ja) | 2016-06-24 | 2021-11-26 | 癌の治療に有用なｐａｒｐ１、ｐａｒｐ２、および／またはチューブリンの阻害剤としてのフタラジン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021192564A Pending JP2022037004A (ja) | 2016-06-24 | 2021-11-26 | 癌の治療に有用なｐａｒｐ１、ｐａｒｐ２、および／またはチューブリンの阻害剤としてのフタラジン誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11072600B2 (enExample) |
| EP (1) | EP3475272B1 (enExample) |
| JP (2) | JP7033588B2 (enExample) |
| KR (1) | KR102494294B1 (enExample) |
| CN (1) | CN109843874B (enExample) |
| AU (1) | AU2017280334C1 (enExample) |
| ES (1) | ES2964531T3 (enExample) |
| HU (1) | HUE066216T2 (enExample) |
| IL (1) | IL263917B (enExample) |
| MX (2) | MX387726B (enExample) |
| PL (1) | PL3475272T3 (enExample) |
| PT (1) | PT3475272T (enExample) |
| SG (1) | SG11201811393WA (enExample) |
| WO (1) | WO2017223516A1 (enExample) |
| ZA (2) | ZA201808562B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3298005B1 (en) | 2015-05-21 | 2024-01-24 | The Regents of The University of California | Anti-cancer compounds |
| CA3043549C (en) | 2015-11-30 | 2023-11-21 | Children's Medical Center Corporation | Compounds for treating proliferative diseases |
| MX387726B (es) * | 2016-06-24 | 2025-03-18 | Univ California | Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer. |
| US11590130B2 (en) | 2018-04-05 | 2023-02-28 | Noviga Research Ab | Combinations of a tubulin polymerization inhibitor and a poly (ADP-ribose) polymerase (PARP) inhibitor for use in the treatment of cancer |
| CN112574122B (zh) * | 2019-09-27 | 2024-05-31 | 上海天慈国际药业有限公司 | 一种奥拉帕尼关键中间体的制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3401171A (en) | 1966-03-11 | 1968-09-10 | Smithkline Corp | 2-amidobenzimidazoles |
| SU1019810A1 (ru) | 1981-07-28 | 1991-04-07 | Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского | Метиловый эфир 5(6)-[1-(2Н)-фталазинонил-4]-1Н-бензимидазолил-2-карбаминовой кислоты, обладающий антигельминтной активностью |
| SU1218649A1 (ru) | 1984-09-19 | 1991-04-30 | Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского | Способ получени метилового эфира 5(6)-[1(2Н)-фталазинонил-4-]-1Н-бензимидазолил-2-карбаминовой кислоты формулы |
| AU2720199A (en) | 1998-02-03 | 1999-08-23 | Boehringer Ingelheim Pharma Kg | Five-membered, benzo-condensed heterocycles used as antithrombotic agents |
| EP1148053A4 (en) | 1999-01-26 | 2002-03-06 | Ono Pharmaceutical Co | 2H-PHTHALAZIN-1-ON DERIVATIVES AND DRUG COMPOSITIONS THAT CONTAIN THESE DERIVATIVES AS ACTIVE INGREDIENTS |
| DE19907813A1 (de) | 1999-02-24 | 2000-08-31 | Boehringer Ingelheim Pharma | Substituierte bicyclische Heterocyclen, deren Herstellung und deren Verwendung als Arzneimittel |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| HU228960B1 (hu) | 2000-10-30 | 2013-07-29 | Kudos Pharm Ltd | Ftalazinon-származékok |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| BRPI0408284B8 (pt) | 2003-03-12 | 2021-05-25 | Kudos Pharm Ltd | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos |
| AU2005244736B2 (en) | 2004-05-07 | 2012-06-28 | Exelixis Patent Company Llc | Raf modulators and methods of use |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| CN101291928A (zh) * | 2005-10-19 | 2008-10-22 | 库多斯药物有限公司 | 4-杂芳甲基取代的酞嗪酮衍生物 |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| RU2490260C2 (ru) * | 2008-03-27 | 2013-08-20 | Янссен Фармацевтика Нв | Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибиторов parp и ингибиторов полимеризации тубулина |
| EP3502707A1 (en) | 2010-01-29 | 2019-06-26 | metanomics GmbH | Means and methods for diagnosing heart failure in a subject |
| CN102372706A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| EP2714703B1 (en) | 2011-05-31 | 2021-03-10 | Newgen Therapeutics, Inc. | Tricyclic inhibitors of poly(adp-ribose)polymerase |
| KR101546743B1 (ko) * | 2012-01-16 | 2015-08-24 | 한국과학기술원 | 인돌 유도체 화합물, 이를 포함하는 Ａｂｌ 키나제 저해제 조성물 및 이상세포 성장 질환의 예방 및 치료용 약학 조성물 |
| WO2014102817A1 (en) * | 2012-12-31 | 2014-07-03 | Cadila Healthcare Limited | Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| MX387726B (es) * | 2016-06-24 | 2025-03-18 | Univ California | Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer. |
-
2017
- 2017-06-23 MX MX2018015893A patent/MX387726B/es unknown
- 2017-06-23 IL IL263917A patent/IL263917B/en unknown
- 2017-06-23 EP EP17737132.5A patent/EP3475272B1/en active Active
- 2017-06-23 AU AU2017280334A patent/AU2017280334C1/en active Active
- 2017-06-23 HU HUE17737132A patent/HUE066216T2/hu unknown
- 2017-06-23 PT PT177371325T patent/PT3475272T/pt unknown
- 2017-06-23 SG SG11201811393WA patent/SG11201811393WA/en unknown
- 2017-06-23 JP JP2019519615A patent/JP7033588B2/ja active Active
- 2017-06-23 KR KR1020197002267A patent/KR102494294B1/ko active Active
- 2017-06-23 ES ES17737132T patent/ES2964531T3/es active Active
- 2017-06-23 US US16/310,606 patent/US11072600B2/en active Active
- 2017-06-23 CN CN201780051422.3A patent/CN109843874B/zh active Active
- 2017-06-23 WO PCT/US2017/039119 patent/WO2017223516A1/en not_active Ceased
- 2017-06-23 PL PL17737132.5T patent/PL3475272T3/pl unknown
-
2018
- 2018-12-17 MX MX2021013641A patent/MX2021013641A/es unknown
- 2018-12-19 ZA ZA2018/08562A patent/ZA201808562B/en unknown
-
2019
- 2019-07-30 US US16/526,620 patent/US10640493B2/en active Active
-
2021
- 2021-07-15 US US17/376,577 patent/US12145925B2/en active Active
- 2021-11-26 JP JP2021192564A patent/JP2022037004A/ja active Pending
-
2023
- 2023-01-25 ZA ZA2023/01066A patent/ZA202301066B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019522681A5 (enExample) | ||
| JP2020125349A5 (enExample) | ||
| JP2017537114A5 (enExample) | ||
| JP5746172B2 (ja) | ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環化合物 | |
| CN111194214A (zh) | 施用sting激动剂的方法 | |
| JP2020508302A5 (enExample) | ||
| CN113316574A (zh) | Shp2抑制剂及其应用 | |
| CN115803325A (zh) | 一种egfr抑制剂及其制备方法和应用 | |
| JP2020514409A5 (enExample) | ||
| RU2010128107A (ru) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp | |
| JP2020504716A5 (enExample) | ||
| JP2019516766A5 (enExample) | ||
| CN114430741A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| CN103124729A (zh) | 作为Axl抑制剂的药物活性化合物 | |
| JP2015518894A5 (enExample) | ||
| JP2013064024A5 (enExample) | ||
| JPWO2021081212A5 (enExample) | ||
| JP2017537080A5 (enExample) | ||
| JP2015518899A5 (enExample) | ||
| JP2015515961A5 (enExample) | ||
| JPWO2019191470A5 (enExample) | ||
| JP2008525530A5 (enExample) | ||
| JP2015524412A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| JPWO2019209896A5 (enExample) |